The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

Dermatologists Raj Chovatiya, MD, PhD, and David Rosmarin, MD, discuss new research outcomes for the topical JAK inhibitor live from the Revolutionizing Atopic Dermatiti 2023 Annual Meeting in Washington, DC.

David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, joins Raj Chovatiya, MD, PhD, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.

Click here to watch the full video of the live RAD 2023 filming.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.